A better therapeutic profile for the combination of mitomycin-C, ifosfamide and cisplatin (MIC) in advanced non-small-cell lung cancer: A useful dose-schedule modification

Annals of Oncology

Volumn 8, Issue 7, 1997, Pages 709-711

  Crino L ^a   Corgna, E ^a   Porrozzi, S ^a   Palladino, M A ^a   Darwish, S ^a   Minotti, V ^a   Mosconi, A M ^a   Tonato, M ^a  

^a Policlinico Hospital   (Italy)

Author keywords

Advanced non small cell lung cancer; Combination chemotherapy; Modified MIC; Nephrotoxicity

Indexed keywords

CISPLATIN; ETOPOSIDE; IFOSFAMIDE; MITOMYCIN C; VINDESINE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CHOICE; DRUG EFFICACY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT PLANNING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IFOSFAMIDE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MITOMYCIN;

EID: 0030768977     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008277604261     Document Type: Article

References (6)

1. Crinò L, Clerici M, Figoli F et al. Chemotherapy of advanced non-small-cell lung cancer: A comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.). Ann Oncol 1995; 6: 347-53.
2. Cullen MH. The MIC regimen in non-small-cell lung cancer. Lung Cancer 1993 (Suppl 2); 9: 81-9.
3. Giron CG, Ordonez A, Jalon JI, Baron MG. Combination chemotherapy with ifosfamide, mitomycin, and cisplatin in advanced non-small-cell lung cancer. Cancer Treat Rep 1987;71: 851-3.
4. Holoye PY, Anderson T, Duelge J et al. Use and safety of high-dose ifosfamide. Semin Oncol 1982; 4 (Suppl 1): 78-86.
5. Wheeler BM, Loehrer PJ, Williams SD et al. Ifosfamide in refractory male germ cell tumors. J Clin Oncol 1986; 4: 28-34.
6. Goren MP, Wright RK, Pratt CB et al. Potentiation of ifosfamide neurotoxicity, hematotoxicity and tubular nephrotoxicity by prior cisdiammine dichloroplatinum therapy. Cancer Res 1987; 47: 1457-60.